Ophthotech, a clinical-stage biotech developing novel therapeutics for eye diseases, filed on Thursday with the SEC to raise up to $85 million in an initial public offering. The New York, NY-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol OPHT. Ophthotech initially filed confidentially on July 15, 2013. Morgan Stanley and J.P. Morgan are the joint bookrunners on the deal. No pricing terms were disclosed.
